Abstract
We report herein the clinical results of a multicenter trial of the Japan Adult Leukemia Study Group for cases of newly diagnosed acute promyelocytic leukemia (APL) treated with all-trans retinoic acid and chemotherapy (JALSG AML-92 study). Of 196 evaluable patients, 173 (88%) achieved complete remission (CR). Multivariate analysis showed that no or minor purpura at diagnosis and age less than 30 years were favorable factors for achievement of CR. There was a significant difference in the 4-year event-free survival between the AML-92 study (54%) and both the AML-87 (32%) and AML-89 (32%) studies which consisted of intensive chemotherapy. Since prognosis in patients with APL largely depends on chemotherapy, it is important to consider more effective chemotherapy during induction and consolidation therapy.
Publication types
-
Clinical Trial
-
Multicenter Study
MeSH terms
-
Aclarubicin / administration & dosage
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cytarabine / administration & dosage
-
Cytarabine / analogs & derivatives*
-
Disease-Free Survival
-
Drug Administration Schedule
-
Female
-
Humans
-
Leukemia, Promyelocytic, Acute / drug therapy*
-
Leukemia, Promyelocytic, Acute / genetics
-
Male
-
Mercaptopurine / administration & dosage
-
Middle Aged
-
Mitoxantrone / administration & dosage
-
Prognosis
-
Receptors, Retinoic Acid / genetics
-
Remission Induction
-
Retinoic Acid Receptor alpha
-
Tretinoin / administration & dosage
-
Tretinoin / therapeutic use*
Substances
-
RARA protein, human
-
Receptors, Retinoic Acid
-
Retinoic Acid Receptor alpha
-
Cytarabine
-
Tretinoin
-
Aclarubicin
-
enocitabine
-
Mitoxantrone
-
Mercaptopurine